

# CURRICULUM VITAE

**Juan Yang, MD, PhD**

Associate Professor/School of Public Health, Fudan University

**Work Address:** No.130 Dong'an Road, Xuhui District, Shanghai, China

**Tel:** +86-15001249320 **Email:** [yangjuan@fudan.edu.cn](mailto:yangjuan@fudan.edu.cn), [yangjuan2016529@126.com](mailto:yangjuan2016529@126.com)

**Gender:** female

**Date of Birth:** Sep 1984

## EDUCATION

---

- PhD, Cancer epidemiology & Health economics, West China School of Public Health, Sichuan University **September 2007-July 2012**
- PhD, Cancer epidemiology & Health economics, jointly trained in Department of Epidemiology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences **October 2008-July 2012**
- Bachelor of Medicine, School of Public Health, Jilin University **September 2002- July 2007**

## PROFESSIONAL TRAINING

---

- Foundation Merieux: 19<sup>th</sup> Advanced Vaccinology Course **Annecy, France May 2018**
- HKU-Pasteur Research Center: short course Surveillance of influenza-like illness **Ho Chi Minh City, Vietnam November 2014**
- Chinese Center for Disease Control and Prevention (Yunnan, China): short course *Estimating the disease burden of influenza* **Yunnan, China Sep 2013**
- London School of Hygiene & Tropical Medicine: short course *Introduction to infectious disease modeling and its application* **London, UK July 2013**

## WORK EXPERIENCE

---

**September 2017 – present**

School of Public Health, Fudan University

**Main duties and responsibilities:** to give lectures on infectious diseases epidemiology, and vaccines; to carry out applied researches to assess the disease burden, epidemiological characteristics of infectious diseases, evaluate the cost-effectiveness of vaccination programme, and analyze the budget impact of immunization programme, in order to provide evidences for policy making on control strategy and measures for infectious diseases.

**July 2012 – August 2017**

Disease Control, Division for Infectious Diseases, Chinese Center for Disease Control and Prevention (China CDC)

**Main duties and responsibilities:** to develop and improve national guidelines for immunization programme of category 2 vaccines in China; to carry out applied researches to assess the disease burden, health impact and economic burden of infectious diseases, estimate the target population size of vaccination, evaluate the cost-effectiveness of vaccination programme, and analyze the budget impact of immunization programme, in order to provide evidences for policy making on control strategy and measures for infectious diseases.

**December 2018- January 2019**

Visiting scholar, Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Paris, France

**Main duties and responsibilities:** modelling the kinetics of neutralizing antibody titres against EV-A71 in Children.

**November 2015- November 2016**

Visiting scholar, Department of Infectious Disease Epidemiology, and Center of Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK

**Main duties and responsibilities:** modelling the potential epidemiological and economic impact of national influenza vaccination programme in China, and analyzing the landscape of diverse regional reimbursement policy for influenza vaccination in China.

## RESEARCH INTERESTS

---

My main research interest is in epidemiology of vaccine and vaccine-preventable infectious diseases (particularly focusing on COVID-19, influenza, respiratory syncytial virus, hand, foot and mouth disease), including disease burden and clinical severity, health-related quality of life, sero-epidemiology, vaccine efficacy/effectiveness/impact, vaccination policy, cost-effectiveness analysis, cost-utility analysis, and budget impact analysis of vaccination, in order to support evidence-based decision making on vaccination programme.

## RESEARCH GRANTS

---

- **Study on Data platform for Key and Major Infectious Diseases.** Funding agency: Shanghai Municipal Science and Technology of China. Total amount: RMB 5,612,700 (Principal investigator)
- **Evaluating the direct and indirect effects of influenza vaccination in Children MCMC-based Bayesian modelling approach** (81903373). Funding agency: National Natural Science Foundation of China. Total amount: RMB 200,000 (Principal investigator)
- **Study on the prediction model and key parameters of emerging infectious disease transmission based on spatiotemporal dynamics** (2018ZX10201001-010). Funding agency: National Science and Technology Major Project of China. Total amount: RMB 2,079,500 (Principal investigator)
- **Expanding the use of seasonal influenza vaccines in public health programs in China, 2013-2016** (1U51IP000819-01). Funding agency: US Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases. Total amount: USD 725,000 (Key investigator)
- **National Science Fund for Distinguished Young Scholars: Epidemiology of infectious diseases, 2016-2020** (No.81525023). Funding agency: Natural Science Foundation of China. Total amount: RMB 4,000,000 (Key investigator)

**PUBLICATIONS as the first/corresponding author in recent 5 years** (†Contributed equally, \*corresponding author)

---

1. **Yang J**†, Liao Q†, Luo K, et al. Seroepidemiology of children with enterovirus A71 infections in southern China: longitudinal, population-based cohort studies, 2013-2018. *Nature Communications*. 2022;13:7280.
2. **Yang J**†, Marziano V†, Deng X, Guzzetta G, Zhang J, Trentini F, Cai J, Poletti P, Zheng W, Wang W, Wu Q, Zhao Z, Dong K, Zhong G, Viboud C, Merler S, Ajelli M and Yu H. Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021. *Nat Hum Behav*. 2021;5:1009-1020.
3. **Yang J**†, Chen X†, Deng X, Chen Z, Gong H, Yan H, Wu Q, Shi H, Lai S, Ajelli M, Viboud C, Yu PH. Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China. *Nat Commun*. 2020; 11(1): 5411.
4. **Yang J**, Atkins KE, Feng L, Baguelin M, Wu P, Yan H, Lau EHY, Wu JT, Liu Y, Cowling BJ, Jit M, Yu H. Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60 years and above in mainland China: a modelling analysis. *BMC Med*. 2020; 18(1): 90.
5. **Yang J**, Zheng W, Shi H, Yan X, Dong K, You Q, Zhong G, Gong H, Chen Z, Jit M, Viboud C, Ajelli M, Yu H. Who should be prioritized for COVID-19 vaccination in China? A descriptive study. *BMC Med*. 2021; 19(1): 45.
6. Cai J†, Deng X†, **Yang J**†, Sun K, Liu H, Chen Z, Peng C, Chen X, Wu Q, Zou J, Sun R, Zheng W, Zhao Z, Lu W, Liang Y, Zhou X, Ajelli M, Yu H. Modeling transmission of SARS-CoV-2 Omicron in China. *Nat Med*. 2022;28(7):1468-1475.
7. Wei X†, **Yang J**†, Gao L, Wang L, Liao Q, Qiu Q, Luo K, Yu S, Zhou Y, Liu F, Chen Q, Zhang J, Dai B, Yang H, Zhou J, Xing W, Chen X, He M, Ren L, Guo J, Luo L, Wu P, Chen Z, van Doorn HR, Cauchemez S, Cowling BJ, Yu H. The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother–neonate cohort study. *The Lancet Infectious Diseases*. 2021; 21(3): 418-426.

8. Jun Cai†, **Yang J†**, Xiaowei Deng, Cheng Peng, Xinhua Chen, Qianhui Wu, Hengcong Liu, Juanjuan Zhang, Wen Zheng, Junyi Zou, Zeyao Zhao, Marco Ajelli, Hongjie Yu. Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China. *Emerging Microbes & Infections*. 2022; 11:1, 1205-1214.
9. Deng X†, **Yang J†**, Wang W†, Wang X†, Zhou J, Chen Z, Li J, Chen Y, Yan H, Zhang J, Zhang Y, Wang Y, Qiu Q, Gong H, Wei X, Wang L, Sun K, Wu P, Ajelli M, Cowling BJ, Viboud C, Yu H. Case fatality risk of the first pandemic wave of novel coronavirus disease 2019 (COVID-19) in China. *Clin Infect Dis*. 2020.
10. Zeng G†, Wu Q†, Pan H†, Li M†, **Yang J†**, Wang L, Wu Z, Jiang D, Deng X, Chu K, Zheng W, Wang L, Lu W, Han B, Zhao Y, Zhu F, Yu H, Yin W. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect Dis*, 2021.
11. Zheng W, Yan X, Zhao Z, **Yang J\***, Yu H. COVID-19 vaccination program in the mainland of China: a subnational descriptive analysis on target population size and current progress. *Infect Dis Poverty*, 2021, 10(1): 124.
12. **Yang J†**, Lau YC†, Wu P, Feng L, Wang X, Chen T, Ali ST, Peng Z, Fang VJ, Zhang J, He Y, Lau EHY, Qin Y, Yang J, Zheng J, Jiang H, Yu H, Cowling BJ. Variation in Influenza B Virus Epidemiology by Lineage, China. *Emerg Infect Dis*. 2018; 24(8): 1536-1540.
13. Kaige Dong, Hui Gong, Guangjie Zhong, Xiaowei Deng, Yuyang Tian, Minghan Wang, Hongjie Yu, **Yang J\***. Estimating mortality associated with seasonal influenza among adults aged 65 years and above in China from 2011 to 2016: A systematic review and model analysis. *Influenza Other Respir Viruses*. 2022; doi: 10.1111/irv.13067.
14. **Yang J**, Gong H, Chen X, Chen Z, Deng X, Qian M, Hou Z, Ajelli M, Viboud C, Yu H. Health-seeking behaviors of patients with acute respiratory infections during the outbreak of novel coronavirus disease 2019 in Wuhan, China. *Influenza Other Respir Viruses*. 2021; 15(2): 188-194.

15. He Y, Liu Y, Dai B, Zhao L, Lin J, **Yang J\***, Yu H\*. Assessing vaccination coverage, timeliness, and its temporal variations among children in a rural area in China. *Hum Vaccin Immunother.* 2021; 17(2): 592-600. *Influenza Other Respir Viruses.* 2022; doi: 10.1111/irv.13067.
16. **Yang J**, Jit M, Zheng Y, Feng L, Liu X, Wu JT, Yu H. The impact of influenza on the health related quality of life in China: an EQ-5D survey. *BMC Infect Dis.* 2017; 17(1): 686.